Multiple Myeloma News and Research

Latest Multiple Myeloma News and Research

Keryx KRX-0401 data in colorectal cancer, multiple myeloma presented at AACR meeting

Keryx Biopharmaceuticals, Inc. today announced that two posters on KRX-0401 were presented at the 102nd annual meeting of the American Association for Cancer Research currently ongoing at the Orange County Convention Center in Orlando, Florida. Perifosine, the Company's novel, potentially first-in-class, oral anti-cancer agent that inhibits Akt activation in the phosphoinositide 3-kinase pathway, is currently in Phase 3 clinical trials for refractory advanced colorectal cancer and multiple myeloma.

6 Apr 2011

Aeterna Zentaris presents two posters on perifosine at AACR meeting

Aeterna Zentaris Inc. today announced that two posters on its lead anticancer agent, perifosine, were presented at the 102nd annual meeting of the American Association for Cancer Research currently held at the Orange County Convention Center in Orlando, Florida.

5 Apr 2011

Synta presents ganetespib and elesclomol study data in cancer at AACR meeting

Synta Pharmaceuticals Corp. today presented five posters at the American Association for Cancer Research 102nd Annual Meeting. Three posters reported results from studies of ganetespib, and two posters reported results from studies of elesclomol, a small-molecule mitochondria metabolism inhibitor.

5 Apr 2011

Risperdal Consta can reduce risk of hospitalisation in patients with schizophrenia

New data from an independent prospective study presented last week at the 19th European Congress of Psychiatry shows treatment with Risperdal Consta is associated with a lower risk of hospitalisation in patients with schizophrenia compared to treatment with other antipsychotics over a 12-month period.

5 Apr 2011

Array BioPharma to unveil new findings about its anti-cancer programs at AACR Annual Meeting

Array BioPharma Inc. today announced that five abstracts have been selected for presentation at the American Association for Cancer Research Annual Meeting, being held from April 2-6, 2010, at the Orange County Convention Center in Orlando, Fla.

2 Apr 2011

Thalidomide provides new hope for patients with difficult to treat liver cancer

Thalidomide has shown potential to be used as the first adjuvant therapy for hepatocellular carcinoma, according to data presented at the International Liver Congress 2011.

2 Apr 2011

Report shows a continued decline in diagnoses, deaths for many types of cancers

Once again, the Annual Report to the Nation on the Status of Cancer shows a continued decline in diagnoses and deaths for many types of cancers. This encouraging news can be attributed primarily to preventive measures such as cessation of smoking and improved diet, and early detection.

2 Apr 2011

EntreMed fourth quarter revenue is $3.7 million for fiscal year 2010

EntreMed, Inc., a clinical-stage pharmaceutical company developing therapeutics for the treatment of cancer, today reported results for the three months and twelve months ended December 31, 2010.

30 Mar 2011

Keryx KRX-0401 trial data against colorectal cancer, multiple myeloma to be presented at AACR

Keryx Biopharmaceuticals, Inc. today announced that two abstracts on KRX-0401 will be presented at the upcoming 102nd annual meeting of the American Association for Cancer Research to be held in Orlando, Florida, from April 2-6, 2011.

29 Mar 2011

Onyx plans to expand carfilzomib Phase 3 European trial in patients with myeloma

Onyx Pharmaceuticals, Inc. today announced its plans to expand the Phase 3 European clinical trial FOCUS, which is evaluating the efficacy and tolerability of carfilzomib, a selective next-generation proteasome inhibitor.

29 Mar 2011

CytRx to present bafetinib preclinical study results at AACR Annual Meeting

CytRx Corporation, a biopharmaceutical company specializing in oncology, today announced that results from a series of preclinical studies demonstrating that its oncology drug candidate bafetinib inhibits bone destruction in model systems is being presented on April 2, 2011 at the American Academy for Cancer Research 102nd Annual Meeting in Orlando, Florida.

29 Mar 2011

MMRF hails new publication of multiple myeloma genome analysis in Nature journal

The Multiple Myeloma Research Foundation today hailed a new publication in Nature as a major step forward in the organization's efforts to advance a personalized medicine approach in multiple myeloma.

24 Mar 2011

New insights into multiple myeloma research

Scientists have unveiled the most comprehensive picture to date of the full genetic blueprint of multiple myeloma, a form of blood cancer. A study of the genomes from 38 cancer samples has yielded new and unexpected insights into the events that lead to this form of cancer and could influence the direction of multiple myeloma research.

24 Mar 2011

Sequencing mouse cancer genome reveals mutations driving cancer in humans

Scientists who pioneered sequencing the genomes of cancer patients to find novel genetic changes at the root of the disease now have turned their attention to a laboratory workhorse — a mouse.

24 Mar 2011

New insights into cancer genome may lead to designer drugs for myeloma

Patients with myeloma could benefit from ‘designer’ drugs in the future after new genome-mapping technology has allowed scientists to identify a full genetic blueprint of the mutations which drive the bone marrow cancer.

23 Mar 2011

$Cancer patients with spinal fractures can benefit from Kyphon Balloon Kyphoplasty$

Cancer patients with spinal fractures can benefit from Kyphon Balloon Kyphoplasty

Medtronic of Canada Ltd. today announced the results of the first randomized, controlled trial comparing Kyphon Balloon Kyphoplasty with non-surgical care in treating spinal fractures in cancer patients.

23 Mar 2011

Cellerant commences CLT-008 Phase I/II trial in patients with leukemia

Cellerant Therapeutics Inc., a biotechnology company developing novel hematopoietic stem cell-based cellular and antibody therapies for blood disorders and cancer, announced the initiation of a Phase I/II clinical trial of CLT-008 in patients receiving intensive post-remission chemotherapy for high-risk leukemia or myelodysplasia.

23 Mar 2011

Sarsia Seed provides follow-up funding for APIM Therapeutics

APIM Therapeutics AS, an early-stage Norwegian therapeutic company, is pursuing a novel drug approach with the ability to potentiate the action of a wide range of chemotherapeutic drugs currently used to treat several types of cancer.

21 Mar 2011

Experts to present latest information on multiple myeloma at Patient Symposium

The Multiple Myeloma Research Foundation and the John Theurer Cancer Center at Hackensack University Medical Center, member of the Multiple Myeloma Research Consortium, will host the MMRF Clinical Insights in Multiple Myeloma Patient Symposium on Saturday, April 2 in Short Hills, NJ from 9:00am-3:30pm.

18 Mar 2011

CTI, Chroma enter agreement to co-develop and license tosedostat

Cell Therapeutics, Inc. and Chroma Therapeutics Ltd. announced today that the companies have entered into a co-development and license agreement providing CTI with exclusive marketing and co-development rights to Chroma's drug candidate tosedostat in North, Central and South America.

14 Mar 2011